--Must See--

Bioinformatics Summer Internship 2024 With Hands-On-Training + Project / Dissertation - 30 Days, 3 Months & 6 Months Duration

The French biotech, OSE Immunotherapeutics which was testing its drug candidate Tedopi’s performance with current standard chemotherapies in patients with advanced or metastatic NSCLC, has now called a halt to the recruitment of patients for the trial as it plans to reconsider the patient profile required.

Because of which the company’s stocks have hit a 5 year low with a 20% plunge.
The drug is in its Phase III of trial in both the US and Europe, while the accrual of patients for the trial has been discontinued, the patients who have already enrolled will continue to receive doses of the drug.

The drug consists of a combination of 10 tumor-associated neo-epitopes designed to activate cytotoxic T cells, to enable them to take on the cancer cells.

“Patients eligible for inclusion in the Atalante 1 study are cancer patients at an advanced stage who have failed a first-line treatment with chemotherapy or failed second-line therapy with checkpoint inhibitors (…). This cancer progression may be difficult to control for some patients in the near-term due to the generally longer-term activity observed with a combination of neoepitopes (…),” stated a press release by the company.

The biotech ensures the safety of existing patients in the trial and is now reviewing available patient data to decide if the trial should be continued as such, or whether it needs

to be reworked to included specific patient sub-groups.

Though time to time reevaluation of goals and strategies is a necessary evil, in case of worst case scenario does come up during this, it could be the end of the vaccine.

In search of the perfect burger. Serial eater. In her spare time, practises her "Vader Voice". Passionate about dance. Real Weird.